Alveolar proteinosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:39 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Alveolar proteinosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Inhaled Molgramostim for Children with Autoimmune Pulmonary Alveolar Proteinosis https://clinicaltrials.eu/trial/study-on-inhaled-molgramostim-for-children-with-autoimmune-pulmonary-alveolar-proteinosis/ Wed, 29 Apr 2026 15:04:27 +0000 https://clinicaltrials.eu/trial/study-on-inhaled-molgramostim-for-children-with-autoimmune-pulmonary-alveolar-proteinosis/ This clinical trial is focused on studying a rare lung condition called Autoimmune Pulmonary Alveolar Proteinosis (aPAP) in children and teenagers. This condition affects the lungs by causing a build-up of proteins and fats, making it difficult to breathe. The study will use a treatment called Molgradex, which is a solution for inhalation containing the active substance molgramostim. This medication is designed to help clear the build-up in the lungs and improve breathing.

The purpose of the study is to evaluate how effective and safe inhaled Molgradex is for young participants with aPAP. Participants in the study will inhale the medication over a period of time, and their progress will be monitored. The study will look at changes in lung function and overall quality of life over 24 and 48 weeks. Participants will have regular check-ups to assess their lung health and any side effects they might experience.

Throughout the study, various health measurements will be taken, such as oxygen levels in the blood and the distance participants can walk in six minutes. The study will also monitor the presence of specific antibodies related to aPAP and any potential side effects, including hypersensitivity and chest pain. The goal is to gather information that could lead to better treatment options for children and teenagers with this rare lung condition.

]]> Study of Inhaled Molgramostim for Adults with Autoimmune Pulmonary Alveolar Proteinosis https://clinicaltrials.eu/trial/study-of-inhaled-molgramostim-for-adults-with-autoimmune-pulmonary-alveolar-proteinosis/ Wed, 29 Apr 2026 14:22:32 +0000 https://clinicaltrials.eu/trial/study-of-inhaled-molgramostim-for-adults-with-autoimmune-pulmonary-alveolar-proteinosis/ This clinical trial is focused on studying a rare lung condition called Autoimmune Pulmonary Alveolar Proteinosis (aPAP). In this condition, the lungs fill with a protein-rich material, making it difficult to breathe. The study is testing a treatment called Molgradex, which is a solution for inhalation containing the active substance molgramostim. This treatment is compared to a placebo, which looks like the treatment but does not contain the active substance.

The purpose of the study is to investigate how effective Molgradex is in treating aPAP compared to the placebo. Participants in the study will inhale the solution once daily. The study will last for several weeks, during which participants will have regular check-ups to monitor their health and the effects of the treatment. The study aims to see if there is an improvement in lung function and overall well-being of the participants.

Throughout the study, participants will undergo various assessments to track changes in their condition. These assessments will help determine if Molgradex can improve breathing and quality of life for those with aPAP. The study is designed to provide valuable information on the potential benefits of this treatment for people living with this rare lung disease.

]]>